Procaps GroupPROC
About: Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Employees: 5,500
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.12% less ownership
Funds ownership: 0.16% [Q2] → 0.03% (-0.12%) [Q3]
43% less funds holding
Funds holding: 7 [Q2] → 4 (-3) [Q3]
81% less capital invested
Capital invested by funds: $453K [Q2] → $86.7K (-$366K) [Q3]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for PROC.